DC
SPRO icon

Diametric Capital’s Spero Therapeutics SPRO Stock Holding History

Diametric Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,700
Closed -$15K – 332
2022
Q2 		$15K Buy
+20,700
New +$60.2K 0.01% 267

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Diametric Capital's SPRO Position: Q3 2022 in Review

Diametric Capital sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 20,700 shares — an estimated $15K sold.

Diametric Capital first reported a position in SPRO in Q2 2022 and held it in 1 quarter. The position peaked at $15K in Q2 2022. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Diametric Capital reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Diametric Capital sold 20,700 Spero Therapeutics shares in Q3 2022, an estimated $15K.
  • Diametric Capital first reported a position in Spero Therapeutics in Q2 2022 and held it in 1 quarter.
  • Diametric Capital's Spero Therapeutics position peaked at $15K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Diametric Capital's 13F filing for Q3 2022, filed 14 Nov 2022.